Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González‐Duarte et al.|The Lancet Neurology|2020Cited by 160
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateAngela Dispenzieri, Soon-Chai Low, Olivier Lairez et al.|Orphanet Journal of Rare Diseases|2022Cited by 91
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin AmyloidosisAngelo Giuseppe Caponetti, D. Eric Steidley, Claudio Rapezzi et al.|JACC Heart Failure|2021Cited by 80
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes SurveyJosé Nativi-Nicolau, D. Eric Steidley, Alfonso Siu et al.|JACC CardioOncology|2021Cited by 61
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Courtney Campbell, Nitasha Sarswat, Samantha LoRusso et al.|Cardiology and Therapy|2022Cited by 51